那格列奈联合甘精胰岛素或中效人胰岛素治疗2型糖尿病的比较  

Comparison of the Therapeutic Effect and Safety Between Glargine and NPH insulin Combined Respectively with Nateglinide in Type 2 Diabetes Mellitus

作　　者：张秀梅[1] 牛建生[1] 师福香 张玲[1] 陈欣[1] 

机构地区：[1]榆林市第二医院内分泌科,陕西榆林719000

出　　处：《延安大学学报（医学科学版）》2009年第3期26-28,共3页Journal of Yan'an University:Medical Science Edition

摘　　要：目的评估甘精胰岛素联合那格列奈在2型糖尿病患者中的降糖和安全性。方法选择血糖控制欠佳的2型糖尿病患者38例,随机分为2组,分别使用甘精胰岛素(Lan组)和中效人胰岛素(NPH组)联合降糖药物那格列奈治疗,疗程16周,观察治疗后空腹血糖(FBG),糖化血红蛋白(HbA1C),体重变化及低血糖的情况。结果两组的空腹血糖均平稳下降,于16周达到稳定,两组终点时FBG、HBA1C、体重指数的比较均无明显统计学差异,但甘精胰岛素的低血糖发生率明显低于NPH组,并且安全达标率显著高于NPH组。结论甘精胰岛素可以使糖尿病患者FBG,HbA1C均达到理想控制目标,而且不增加体重,低血糖发生率低,使用方便,患者满意度更高。Objective To compare the therapeutic effects and safety between glargine and NPH insulin combined respectively with natelinide in type 2 diabetes mellitus.Methods Thirty-eight patients with type 2 diabetes in poor plasma glucose control(HBA1c>7.0 %) were randomly divided into two groups,recieving insulin glargine combined with natelinide(Lan group) or NPH insulin combined with natelinide(NPH group).During a treatment of 16 weeks,the changes of fasting blood glucose(FBG),glycosylated hemoglobin A1c(HbA1c) as well as body wiehgt and the occurence of hypoglycemia were recorded.Results The FBG in both groups decreased smoothly and achieved steadiness at the end of 16 weeks.There was no significant difference in the comparision of FBG,HbA1c and body mass index(BMI) between two groups.However,the safety achieving rate of Lan group was remarkably higher than that of NPH group,with the occurence rate of hypoglycemia obviously lower than that in NPH group.Conclusion The combination of glargine with natelinide can control FBG and HbA1c to a ideal target range,with no increase of body weight,low occurence of hypoglycemia and convenience in clinical practice,therefor can has a better degree of satisfaction in patients with type 2 Diabetes Mellitus.

关 键 词：甘精胰岛素 那格列奈 2型糖尿病 中效人胰岛素 

分 类 号：R587.1[医药卫生—内分泌]